113 related articles for article (PubMed ID: 6547647)
1. The effect of radioiodine and antithyroid drugs on serum long acting thyroid stimulator protector (IATS-P). A three year prospective study.
Hardisty CA; Fowles A; Munro DS
Clin Endocrinol (Oxf); 1984 May; 20(5):597-605. PubMed ID: 6547647
[TBL] [Abstract][Full Text] [Related]
2. The prediction of relapse after drug treatment of Graves' disease by assay of long acting thyroid stimulator-protector (LATS-P).
Hardisty CA; Hanford L; Munro DS
Clin Endocrinol (Oxf); 1981 May; 14(5):509-17. PubMed ID: 6895487
[TBL] [Abstract][Full Text] [Related]
3. Radioiodine therapy in Graves' disease patients with large diffuse goiters treated with or without carbimazole at the time of radioiodine therapy.
Sabri O; Zimny M; Schreckenberger M; Reinartz P; Ostwald E; Buell U
Thyroid; 1999 Dec; 9(12):1181-8. PubMed ID: 10646656
[TBL] [Abstract][Full Text] [Related]
4. Long-acting thyroid stimulator (LATS) and long acting thyroid stimulator protector (LATS-P) in untreated thyrotoxicosis.
Hardisty CA; Hanford L; Humphries H; Munro DS
Clin Endocrinol (Oxf); 1981 Jun; 14(6):631-9. PubMed ID: 6895353
[TBL] [Abstract][Full Text] [Related]
5. Serum long acting thyroid stimulator protector in pregnancy complicated by Graves' disease.
Hardisty CA; Munro DS
Br Med J (Clin Res Ed); 1983 Mar; 286(6369):934-5. PubMed ID: 6403139
[TBL] [Abstract][Full Text] [Related]
6. Serum long acting thyroid stimulator (LATS) and LATS-protector (LATS-P) in Graves' disease associated with localized myxedema.
Hardisty CA; Fowles A; Munro DS
J Endocrinol Invest; 1984 Apr; 7(2):151-5. PubMed ID: 6547156
[TBL] [Abstract][Full Text] [Related]
7. Relation of thyroid-stimulating immunoglobulins to thyroid function and effects of surgery, radioiodine, and antithyroid drugs.
Mukhtar ED; Smith BR; Pyle GA; Hall R; Vice P
Lancet; 1975 Mar; 1(7909):713-5. PubMed ID: 47482
[TBL] [Abstract][Full Text] [Related]
8. Thyrotrophin binding inhibiting immunoglobulins in Graves' disease before, during and after antithyroid therapy, and its relation to long-acting thyroid stimulator.
Docter R; Bos G; Visser TJ; Hennemann G
Clin Endocrinol (Oxf); 1980 Feb; 12(2):143-53. PubMed ID: 6105023
[TBL] [Abstract][Full Text] [Related]
9. Influence of prior carbimazole on the outcome of radioiodine therapy in pediatric and adolescent Graves' disease.
Ballal S; Soundararajan R; Singh H; Garg A; Chopra S; Bal C
Nucl Med Commun; 2015 Jun; 36(6):566-72. PubMed ID: 25757198
[TBL] [Abstract][Full Text] [Related]
10. Prediction of outcome in Graves' disease after carbimazole treatment.
Weetman AP; Ratanachaiyavong S; Middleton GW; Love W; John R; Owen GM; Darke C; Lazarus JH; Hall R; McGregor AM
Q J Med; 1986 Apr; 59(228):409-19. PubMed ID: 2875484
[TBL] [Abstract][Full Text] [Related]
11. Dissociation of serum LATS activity and hyperfunction and autonomy of the thyroid gland in Graves' disease.
Hennemann G; Dolman A; Docter R; De Reus A; Van Zijl J
J Clin Endocrinol Metab; 1975 Jun; 40(6):935-41. PubMed ID: 1173367
[TBL] [Abstract][Full Text] [Related]
12. Radioiodine therapy compared in patients with toxic nodular or Graves' hyperthyroidism.
Franklyn JA; Daykin J; Holder R; Sheppard MC
QJM; 1995 Mar; 88(3):175-80. PubMed ID: 7767667
[TBL] [Abstract][Full Text] [Related]
13. Long-acting thyroid stimulator and related factors.
Kendall-Taylor P; Dirmikis SM; Munro DS
Proc R Soc Med; 1975 Apr; 68(4):252-3. PubMed ID: 1242809
[No Abstract] [Full Text] [Related]
14. Optimum duration of antithyroid drug treatment determined by assay of thyroid stimulating antibody in patients with Graves' disease.
Edan G; Massart C; Hody B; Poirier JY; Lé Reun M; Hespel JP; Leclech G; Simon M
BMJ; 1989 Feb; 298(6670):359-61. PubMed ID: 2564286
[TBL] [Abstract][Full Text] [Related]
15. [Characterization of therapy failures in radioiodine therapy of Graves' disease without simultaneous antithyroid agents].
Sabri O; Zimny M; Schreckenberger M; Reinartz P; Nowak B; Ostwald E; Schäfer W; Block S; Setani K; Büll U
Nuklearmedizin; 2001 Feb; 40(1):1-6. PubMed ID: 11373933
[TBL] [Abstract][Full Text] [Related]
16. Different strategies to overcome the effect of carbimazole on high- and low-dose radioiodine therapy: results from continuous dose-effect models.
Walter MA; Schindler C; Christ-Crain M; Müller-Brand J; Müller B
Eur J Clin Invest; 2009 Jan; 39(1):51-7. PubMed ID: 19087129
[TBL] [Abstract][Full Text] [Related]
17. [Long term effects of the treatment of the Graves' disease by 4 different therapeutics (author's transl)].
Mornex R; Quintana J; Chavrier B
Ann Endocrinol (Paris); 1977; 38(4):273-82. PubMed ID: 578399
[TBL] [Abstract][Full Text] [Related]
18. The effect of partial thyroidectomy for Graves' disease on serum long-acting thyroid stimulator protector (LATS-P).
Hardisty CA; Talbot CH; Munro DS
Clin Endocrinol (Oxf); 1981 Feb; 14(2):181-8. PubMed ID: 6894891
[TBL] [Abstract][Full Text] [Related]
19. Late and transient increases in free T4 after radioiodine treatment for Graves' disease.
Stensvold AD; Jorde R; Sundsfjord J
J Endocrinol Invest; 1997 Nov; 20(10):580-4. PubMed ID: 9438914
[TBL] [Abstract][Full Text] [Related]
20. The effect of antithyroid drug pretreatment on acute changes in thyroid hormone levels after (131)I ablation for Graves' disease.
Burch HB; Solomon BL; Cooper DS; Ferguson P; Walpert N; Howard R
J Clin Endocrinol Metab; 2001 Jul; 86(7):3016-21. PubMed ID: 11443161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
